NKGen Biotech CEO Paul Song has invested $2.65 million of his personal funds to accelerate the company's phase 2 Alzheimer's disease cell therapy trial amid significant financial challenges.
NKGen Biotech's innovative NK cell therapy troculeucel has received FDA Fast Track Designation for treating moderate Alzheimer's disease, potentially accelerating its development pathway.
The NK cell therapy field is experiencing significant growth, driven by its potential to address unmet needs in cancer treatment with safer, more targeted options.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.